1.To examine the rationale and trial design of a Phase I trial of a PARP inhibitor, radiation, and immunotherapy in small cell lung cancer

2.To describe cost implications of frontline treatment with combination immunotherapy and chemotherapy for non-small cell lung cancer

3. To discuss a rules-based algorithm to identify patients most in need of advance care planning, as well as implementation of interventions



Session date: 
07/24/2017 - 12:00pm to 1:00pm CDT
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Christine Bestvina, MD